Bioserv Corporation Sustainability Profile
Bioserv Corporation, also known as Bioserv America, is a leading provider of biopharmaceutical manufacturing solutions, headquartered in the United States. Established in 1998, the company has made significant strides in the biopharma industry, focusing on contract manufacturing, process development, and regulatory support for biologics and advanced therapies. With operational facilities strategically located across the US, Bioserv Corporation is renowned for its commitment to quality and innovation. The company offers a unique blend of services, including cell culture, purification, and fill-finish capabilities, tailored to meet the specific needs of its clients. Bioserv's dedication to excellence has positioned it as a trusted partner in the biopharmaceutical sector, earning accolades for its robust quality systems and successful project deliveries. As the industry continues to evolve, Bioserv remains at the forefront, driving advancements in biomanufacturing.
DitchCarbon Score
How does Bioserv Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bioserv Corporation's score of 25 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bioserv Corporation's reported carbon emissions
Bioserv Corporation, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Sorrento Therapeutics, Inc., which may influence its climate commitments and reporting practices. While there are no documented reduction targets or climate pledges from Bioserv Corporation, it is important to note that the broader industry context often drives companies to adopt sustainability initiatives. As a subsidiary, Bioserv may align its climate strategies with those of Sorrento Therapeutics, which could include participation in initiatives such as the Carbon Disclosure Project (CDP) at the cascade level of 1. In summary, while specific emissions data and reduction targets for Bioserv Corporation are not available, the company is positioned within a corporate family that may influence its climate commitments and sustainability practices.
How Carbon Intensive is Bioserv Corporation's Industry?
How Carbon Intensive is Bioserv Corporation's Location?
Bioserv Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bioserv Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
